CN1772074A - Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying - Google Patents
Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying Download PDFInfo
- Publication number
- CN1772074A CN1772074A CNA2004100097592A CN200410009759A CN1772074A CN 1772074 A CN1772074 A CN 1772074A CN A2004100097592 A CNA2004100097592 A CN A2004100097592A CN 200410009759 A CN200410009759 A CN 200410009759A CN 1772074 A CN1772074 A CN 1772074A
- Authority
- CN
- China
- Prior art keywords
- flos
- chinese medicine
- medicine composition
- angelicae sinensis
- mammary gland
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 206010046798 Uterine leiomyoma Diseases 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 210000005075 mammary gland Anatomy 0.000 title claims abstract description 11
- 230000001105 regulatory effect Effects 0.000 title abstract description 3
- 230000005906 menstruation Effects 0.000 title abstract 2
- 230000008961 swelling Effects 0.000 title 1
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 241000628997 Flos Species 0.000 claims description 96
- 240000008669 Hedera helix Species 0.000 claims description 16
- 210000000582 semen Anatomy 0.000 claims description 13
- 241000283956 Manis Species 0.000 claims description 12
- 201000005630 leukorrhea Diseases 0.000 claims description 6
- 206010046901 vaginal discharge Diseases 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 230000002175 menstrual effect Effects 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000220317 Rosa Species 0.000 abstract 1
- 240000008254 Rosa chinensis Species 0.000 abstract 1
- 235000000664 Rosa chinensis Nutrition 0.000 abstract 1
- 241000046198 Triteleia hyacinthina Species 0.000 abstract 1
- 230000000474 nursing effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 27
- 208000029312 Muscular tumor Diseases 0.000 description 11
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 10
- 210000000481 breast Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 7
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 7
- 229940028334 follicle stimulating hormone Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 210000002445 nipple Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 208000007106 menorrhagia Diseases 0.000 description 5
- 239000000186 progesterone Substances 0.000 description 5
- 229960003387 progesterone Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 2
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
- 206010006312 Breast swelling Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 201000004458 Myoma Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- -1 after concentrating Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229950002007 estradiol benzoate Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical group C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 239000008956 guizhi-fuling Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses one kind of Chinese medicine composition prepared with 11 kinds of Chinese medicinal materials, including angelica, safflower, rose, Chinese rose, white hyacinth flower, etc in certain weight proportion. The Chinese medicine composition may be prepared into capsule, tablet, bolus, oral liquid, etc. The present invention has the functions of promoting blood circulation, restoring menstrual flow, invigorating vital energy, nourishing blood, etc. and is used in treating hysteromyoma and mammary gland intumescence, regulating menstruation, stopping leukorrhagia, beautifying and nursing face.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, is a kind of Chinese medicine composition that is used to prevent and treat hysteromyoma, mammary gland enlargement specifically, also has the effect of adjusting meridian and stopping leukorrhea, looks improving and the skin nourishing simultaneously.
Background technology
Hysteromyoma is the abbreviation of leiomyoma of uterus, is modal female sex organ benign tumor, is mainly in middle-aged women.Generation that it is generally acknowledged hysteromyoma may be in close relations with estrogen, and the part exists high concentration estrogen easily to stimulate the smooth muscle fiber hypertrophy.The size of hysteromyoma is not proportional with symptom, different clinical manifestations is arranged usually: the general non-evident sympton of (1) Subserous myoma owing to the muscular tumor growth site is different.(2) intramural myoma is at hour non-evident sympton, muscular tumor the grow up visible menorrhagia in back, menostaxis and lower abdomen bearing down, leucorrhoea grow in quantity, even can cause infertile.(3) fleshy polyp can cause menorrhagia, menostaxis, the caused anemia that the course of disease is long, infertile and easily miscarriage.(4) the cervix uteri muscular tumor can cause frequent micturition, urine retention, constipation etc.
In general the treatment of hysteromyoma divides operation and non-operative treatment, operative treatment comprises myomatectomy, panhysterectomy etc., non-operative treatment multiselect hormone medicine, as: danazol, gossypol etc., or take tcm syndrome differentiation and treatment, and it is generally acknowledged primary disease Shu “ mass in the abdomen in theory of Chinese medical science " category, how to cause; treat based on regulating qi-flowing for activating stagnancy, promoting blood circulation and breaking stagnation eliminating stagnation by the stagnation of QI, blood stasis, phlegm-damp, as: GUIZHI FULING JIAONANG and GONGLIUQING capsule etc.
Children's was born back 3～5 days, no matter be girl baby or boy baby, the phenomenon of breast swelling appears in the meeting that has, be generally the bilateral symmetric property enlargement, size differs in size as Semen Viciae fabae to Ovum Coturnicis japonicae, also can secrete a small amount of milk sometimes, and quantity does not wait from several to 1～2 milliliter, generally giving birth to the most obvious in the time of 8～18 days, 2～3 weeks back Lock-out in back, minority also just disappeared possibly in lasting about 1 month.The phenomenon of this mammary gland enlargement is a kind of normal physiological phenomenon, is called the enlargement of physiological mammary gland, and this is subjected to for neonate can to disappear voluntarily in 2～3 weeks due to the influence of parent estrogen before death, need not treat, and must guard against extruding in order to avoid infect.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition that is used to prevent and treat hysteromyoma, mammary gland enlargement and adjusting meridian and stopping leukorrhea, looks improving and the skin nourishing.
The invention provides a kind of Chinese medicine composition that is used to prevent and treat hysteromyoma, mammary gland enlargement and adjusting meridian and stopping leukorrhea, looks improving and the skin nourishing.It is made up of active ingredient and/or pharmaceutically acceptable carrier, it is characterized in that: made by following raw materials by weight proportions: Radix Angelicae Sinensis 1-50 part, Flos Carthami 1-50 part, Flos Rosae Rugosae 1-50 part, Flos Rosae Chinensis 1-50 part, Flos Semen Lablab Album 1-50 part, Flos Celosiae Cristatae 1-50 part, Squama Manis 1-50 part, Semen Vaccariae 1-50 part, Flos Chrysanthemi 1-50 part, Flos Sophorae 1-50 part, Radix Glycyrrhizae Preparata 1-50 part.
Wherein preferred, Radix Angelicae Sinensis 12-38 part, Flos Carthami 1-16 part, Flos Rosae Rugosae 1-14 part, Flos Rosae Chinensis 1-8 part, Flos Semen Lablab Album 1-20 part, Flos Celosiae Cristatae 1-19 part, Squama Manis 1-15 part, Semen Vaccariae 1-12 part, Flos Chrysanthemi 1-22 part, Flos Sophorae 1-10 part, Radix Glycyrrhizae Preparata 1-10 part.
Wherein said Flos Semen Lablab Album can substitute with Spica Prunellae; Radix Angelicae Sinensis can substitute with Radix Salviae Miltiorrhizae.
Chinese medicine composition of the present invention can be made various common formulations together with its effective ingredient and/or acceptable accessories, as capsule, tablet, pill, oral liquid etc.
The present invention by animal experiment and clinical observation have promoting blood circulation to restore menstrual flow, benefiting qi and nourishing blood, clots absorbing collateral dredging, the effect of the long-pending piece that dissipates, available prevention and treatment hysteromyoma, mammary gland enlargement, and can adjusting meridian and stopping leukorrhea, looks improving and the skin nourishing.
Specific embodiment
Embodiment 1: the preparation of capsule of the present invention
Take by weighing following materials of weight proportions medicine: Radix Angelicae Sinensis 35g, Flos Carthami 50g, Flos Rosae Rugosae 50g, Flos Rosae Chinensis 50g, Flos Semen Lablab Album 45g, Flos Celosiae Cristatae 50g, Squama Manis 1g, Semen Vaccariae 10g, 45 parts of Flos Chrysanthemis, Flos Sophorae 45g, Radix Glycyrrhizae Preparata 35g, carry out preliminary working with Radix Angelicae Sinensis, Flos Carthami, Flos Rosae Rugosae, Flos Rosae Chinensis, Flos Semen Lablab Album, Flos Celosiae Cristatae, Squama Manis, Semen Vaccariae, Flos Chrysanthemi, Flos Sophorae, Radix Glycyrrhizae Preparata; The medicine that then processing is cooked drops into multi-function extractor, the water that adds 3-8 times of drug weight, heat and decoct boiling back 25 minutes to 3 hours after-filtration of slow fire for the first time, the water that adds for the second time 3-6 times of drug weight, back 25 minutes to 3 hours after-filtration seethe with excitement, the same for the third time, after three times three filtered medicine liquid being dropped into vacuum concentrator concentrates, after concentrating, extract to drop in the jacketed pan and carry out water evaporates, put into the heated drying case again, temperature in the drying baker is controlled between the 40-70 degree, take out after 5-8 hour, planar, again through pulverizing, sieve, add adjuvant (starch, PVP etc.) make granule, above-mentioned granule pack in the hungry area softgel shell capsule.
Embodiment 2: the preparation of tablet of the present invention
Take by weighing following materials of weight proportions medicine: Radix Angelicae Sinensis 45g, Flos Carthami 5g, Flos Rosae Rugosae 15g, Flos Rosae Chinensis 15g, Flos Semen Lablab Album 10g, Flos Celosiae Cristatae 25g, Squama Manis 10g, Semen Vaccariae 1g, Flos Chrysanthemi 25g, Flos Sophorae 15g, Radix Glycyrrhizae Preparata 15g, carry out preliminary working with Radix Angelicae Sinensis, Flos Carthami, Flos Rosae Rugosae, Flos Rosae Chinensis, Flos Semen Lablab Album, Flos Celosiae Cristatae, Squama Manis, Semen Vaccariae, Flos Chrysanthemi, Flos Sophorae, Radix Glycyrrhizae Preparata; The medicine that then processing is cooked drops into multi-function extractor, the water that adds 3-8 times of drug weight, heat and decoct boiling back 25 minutes to 3 hours after-filtration of slow fire for the first time, the water that adds for the second time 3-6 times of drug weight, back 25 minutes to 3 hours after-filtration seethe with excitement, the same for the third time, after three times three filtered medicine liquid are dropped into vacuum concentrator and concentrate, after concentrating, extract to drop in the jacketed pan and carry out water evaporates, put into the heated drying case again, temperature in the drying baker is controlled between the 40-70 degree, take out after 5-8 hour, planar, again through pulverizing, sieve, add adjuvant (starch, PVP etc.) making granule, is slabbing after compressing.
Embodiment 3: the preparation of pill of the present invention
Take by weighing following materials of weight proportions medicine: Radix Angelicae Sinensis 1g, Flos Carthami 35g, Flos Rosae Rugosae 35g, Flos Rosae Chinensis 15g, Flos Semen Lablab Album 50g, Flos Celosiae Cristatae 15g, Squama Manis 10g, Semen Vaccariae 35g, Flos Chrysanthemi 50g, Flos Sophorae 50g, Radix Glycyrrhizae Preparata 50g, carry out preliminary working with Radix Angelicae Sinensis, Flos Carthami, Flos Rosae Rugosae, Flos Rosae Chinensis, Flos Semen Lablab Album, Flos Celosiae Cristatae, Squama Manis, Semen Vaccariae, Flos Chrysanthemi, Flos Sophorae, Radix Glycyrrhizae Preparata; The medicine that then processing cooked is pulverized, is sieved, and sterilizes again, put in right amount at last the Mel of perfecting mix the back pill.
Embodiment 4: the preparation of oral liquid of the present invention
Take by weighing following materials of weight proportions medicine: Radix Angelicae Sinensis 50g, Flos Carthami 10g, Flos Rosae Rugosae 45g, Flos Rosae Chinensis 35g, Flos Semen Lablab Album 50g, Flos Celosiae Cristatae 35g, Squama Manis 50g, Semen Vaccariae 50g, Flos Chrysanthemi 50g, Flos Sophorae 35g, Radix Glycyrrhizae Preparata 45g, Radix Angelicae Sinensis, Flos Carthami, Flos Rosae Rugosae, Flos Rosae Chinensis, Flos Semen Lablab Album, Flos Celosiae Cristatae, Squama Manis, Semen Vaccariae, Flos Chrysanthemi, Flos Sophorae, Radix Glycyrrhizae Preparata are boiled decocting three times, filter, merging filtrate, concentrate, add sweeting agent Mel and diluent water and make oral liquid.
Embodiment 5: the preparation of capsule of the present invention
According to embodiment 1 described method, difference is to select following materials of weight proportions medicine for use: Radix Angelicae Sinensis 12g, Flos Carthami 1g, Flos Rosae Rugosae 14g, Flos Rosae Chinensis 1g, Spica Prunellae 20g, Flos Celosiae Cristatae 19g, Squama Manis 5g, Semen Vaccariae 12g, Flos Chrysanthemi 1g, Flos Sophorae 10g, Radix Glycyrrhizae Preparata 1g.
Embodiment 6: the preparation of tablet of the present invention
According to embodiment 2 described methods, difference is to select following materials of weight proportions medicine for use: Radix Angelicae Sinensis 38g, Flos Carthami 16g, Flos Rosae Rugosae 1g, Flos Rosae Chinensis 8g, Flos Semen Lablab Album 1g, Flos Celosiae Cristatae 1g, Squama Manis 15g, Semen Vaccariae 1g, Flos Chrysanthemi 22g, Flos Sophorae 1g, Radix Glycyrrhizae Preparata 10g.
Embodiment 7: the preparation of pill of the present invention
According to embodiment 3 described methods, difference is to select following materials of weight proportions medicine for use: Radix Angelicae Sinensis 24g, Flos Carthami 14g, Flos Rosae Rugosae 4g, Flos Rosae Chinensis 6g, Flos Semen Lablab Album 12g, Flos Celosiae Cristatae 14g, Squama Manis 10g, Semen Vaccariae 12g, Flos Chrysanthemi 20g, Flos Sophorae 5g, Radix Glycyrrhizae Preparata 5g.
Embodiment 8: the preparation of oral liquid of the present invention
According to embodiment 4 described methods, difference is to select following materials of weight proportions medicine for use: Radix Salviae Miltiorrhizae 23g, Flos Carthami 10g, Flos Rosae Rugosae 12g, Flos Rosae Chinensis 3g, Spica Prunellae 12g, Flos Celosiae Cristatae 10g, Squama Manis 5g, Semen Vaccariae 12g, Flos Chrysanthemi 13g, Flos Sophorae 2g, Radix Glycyrrhizae Preparata 2g.
Below set forth the effect of this Chinese medicine composition by test.
Experimental example 1:
1 material
1.1 medicine and reagent
BUPIXIAO PIAN is provided by Shenyang Traditional Chinese Medicine Factory of northeast pharmacy group company.Estradiol benzoate injection, the 9th pharmaceutical factory provides by Shanghai.Progesterone injection is provided by fairy house pharmaceutical factory of Zhejiang medicine limited company.Estradiol (E2) radioimmunoassay kit, Chinese Academy of Medical Sciences nuclear medicine technology center, Science and Technology Ltd. of Concord Hospital provide.Progesterone (P), follicle stimulating hormone (FSH) are measured box, are provided by the Beijing North biotechnology research.
1.2 animal
The Wistar female rats, body weight 160-200g, Chinese Academy of Sciences animal provides.
2 methods
Get 60 of rats, be divided into 6 groups at random, be respectively normal control group, model control group, three dosage groups of the present invention (0.5g/kg, 1g/kg, 2g/kg), BUPIXIAO PIAN 1.04g/kg group, 10 every group.Normal control treated animal intramuscular injection normal saline 0.1ml/ only, every day 1 time, continuous 30 days, other each intramuscular injection estradiol benzoate 0.5mg/kg, every day 1 time, continuous 25 days, intramuscular injection Progesterone 4mg/kg subsequently, every day 1 time, continuous 5 days.From modeling the 1st day, each organized administration 1ml/100g, every day 1 time, and continuous 33 days, after the last administration 1 hour, pentobarbital sodium 30mg/kg anesthesia, abdominal aortic blood, separation of serum is exempted from method mensuration serum E with putting
2, P, FSH.Respectively at measuring first pair of breast diameter of every rat chest and height of nipples value with precision vernier callipers before and after the administration.
3 results
3.1 influence (seeing Table 1) to breast diameter and height of nipples
The influence of table 1 pair breast diameter and height of nipples (x ± s)
| Group | Dosage (g/kg) | Breast diameter | Height of nipples | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Normal group model control group breast addiction disappears and organizes of the present invention group | 1.04 0.5 1 2 | 0.96± 0.12 1.07± 0.32 1.02± 0.41 0.99± 0.33 1.08± 0.32 1.02± 0.42 | 1.03± 0.17 1.96± 0.20## 1.68± 0.26 * 1.73± 0.21 * 1.64± 0.26 * 1.66± 0.33 * | 1.72± 0.31 1.69± 0.22 1.68± 0.23 1.70± 0.29 1.71± 0.25 1.71± 0.31 | 1.75±0.26 2.13± 0.16## 1.87±0.26 * 1.92± 0.13 ** 1.83±0.21 * 1.80± 0.19 ** |
Compare with model control group
*P＜0.05,
*P＜0.01
Compare ##P＜0.01 with the normal control group
As seen from the above table, the obvious enlargement of animal injection estrogen rear udder attachment, breast diameter and height of nipples all significantly increase than normal group, and BUPIXIAO PIAN can suppress the breast swelling that estrogen causes, the present invention's three dosage groups breast diameter and height of nipples all obviously reduce (P＜0.05, P＜0.01).
3.2 influence (seeing Table 2) to sex hormone level
The influence of table 2 pair cyclomastopathy rat gonadal hormone (n=10, x ± s)
| Group | Dosage (g/kg | E 2 (pg/ml) | P (ng/ml) | FSH (mIU/ml) |
| ) | ||||
| Normal group model control group breast addiction disappears and organizes of the present invention group | -- -- 1.04 0.5 1 2 | 4.58±7.52 23.56±12.21## 18.75±14.32 18.71±14.62 16.25±13.54 10.21±5.32 ** | 7.62±5.84 2.11±0.54## 2.52±0.98 2.41±0.65 2.46±1.41 3.26±1.29 * | 1.39±0.48 0.98±0.33# 1.62±0.44 ** 1.61±0.39 ** 1.63±0.52 ** 1.59±0.34 ** |
Annotate: compare with model control group,
*P＜0.05,
*P＜0.01.
As seen from the above table, hyperplasia of mammary gland model group and normal group compare, serum estradiol (E
2) content significantly increases (P＜0.01), progesterone (P) and follicle stimulating hormone (FSH) content significantly reduce (P＜0.05, P＜0.01), after BUPIXIAO PIAN and the present invention's treatment, follicle stimulating hormone content all obviously increases, and the BUPIXIAO PIAN high dose can also make that estradiol content obviously reduces, progesterone content obviously raises.
4. conclusion
Can be reached a conclusion by this test, the present invention has good preventive and therapeutic effect to the experimental rat cyclomastopathy.
Experimental example 2:
1 data and method
1.1 object of study and grouping
Select Symptomatic patients with uterine myoma 120 examples, make a definite diagnosis through gynecologial examination and B ultrasonic,, 33～55 years old age.Main suit's excessive menstruation 97 examples wherein, dysmenorrhea 72 examples have lower abdomen to weigh down 85 examples that expand.Be divided into 2 groups at random, be respectively treatment group of the present invention and matched group, two groups of patient's age, body weight, the inferior credits by statistics of motherhood are analysed, and difference does not have significance.
1.2 method
Of the present invention group: take oral liquid of the present invention from first day of menstrual cycle, every day 3 times, each 23g took 6 months continuously.
The mifepristone group: every day 1 time, each 12.5mg takes from first day of menstrual cycle, takes continuously 6 months.
Regularly did B ultrasonic before two groups of patient treatments and during the treatment in every month and measure the volume of uterus and hysteromyoma, blood drawing have a blood test routine, hepatic and renal function, survey routine urinalysis are observed clinical symptoms, medicine side reaction, and are advised patient's period in a medicine person if discomfort is arranged with examining.
1.3 curative effect judging standard:
Muscular tumor volume (V)=A*B*C* π/6
(A, B, C represent the radius of the three-dimensional radial line of muscular tumor respectively)
Muscular tumor volume-diminished rate (%)=(1-V
x/ V
0) * 100%
(V
0The volume of muscular tumor before the representative treatment, V
xThe muscular tumor volume that records after the representative treatment)
To myomatosis, the volume that calculates maximum muscular tumor as a result of.
2 results
2.1 treatment back hysteromyoma dwindles degree (seeing Table 1)
Uterus and hysteromyoma volume situation (cm before and after table 1 treatment
3, x ± s)
| Group | Uterine volume | The hysteromyoma volume | Hysteromyoma dwindles percentage rate | |
| Of the present invention group | Before the treatment | 382.17±113.21 | 142.31±79.82 | -- |
| After the treatment | 298.13± 102.54 ** | 89.73±46.25 ** | 0.423±0.154 | |
| The mifepristone group | Before the treatment | 376.25±127.81 | 138.24±88.21 | -- |
| After the treatment | 278.15± 113.84 ** | 74.56±33.12 ** | 0.457±0.105 | |
With treatment is relatively preceding on the same group,
*P＜0.01
As seen from the above table, treat back uterine volume and muscular tumor volumes and before the treatment significant difference (P＜0.01) is arranged more all on the same group for two groups; Two groups of tumor body minifications compare there was no significant difference (P＞0.05).
2.2 doing well,improving situation after the medication
The medication of treatment group played menstrual blood volume in the second month and reduces gradually, and the dysmenorrhea symptom all disappears, and lower abdomen weighs down to expand and obviously alleviates.Menstrual blood volume also reduces gradually after the matched group medication, and the dysmenorrhea symptom all disappears, and lower abdomen weighs down to expand and obviously alleviates.
2.3 side reaction situation
Matched group 6 examples have slight hectic fever sense, and sense was felt sick when 2 example beginnings were taken medicine in several days, and the back of continuing to take medicine disappears.Do not see lesions of liver and kidney; Treatment group patient of the present invention does not see obvious adverse reaction.
3. conclusion
The present invention has the obvious treatment hysteromyoma, improves the effect of dysmenorrhea symptom, and does not have side reaction.
Claims (5)
1, a kind of Chinese medicine composition that is used to prevent and treat hysteromyoma, mammary gland enlargement and energy adjusting meridian and stopping leukorrhea, looks improving and the skin nourishing, it is made up of active ingredient and/or pharmaceutically acceptable carrier, it is characterized in that: made by following raw materials by weight proportions: Radix Angelicae Sinensis 1-50 part, Flos Carthami 1-50 part, Flos Rosae Rugosae 1-50 part, Flos Rosae Chinensis 1-50 part, Flos Semen Lablab Album 1-50 part, Flos Celosiae Cristatae 1-50 part, Squama Manis 1-50 part, Semen Vaccariae 1-50 part, Flos Chrysanthemi 1-50 part, Flos Sophorae 1-50 part, Radix Glycyrrhizae Preparata 1-50 part.
2, Chinese medicine composition according to claim 1 is characterized in that: made by following raw materials by weight proportions: Radix Angelicae Sinensis 12-38 part, Flos Carthami 1-16 part, Flos Rosae Rugosae 1-14 part, Flos Rosae Chinensis 1-8 part, Flos Semen Lablab Album 1-20 part, Flos Celosiae Cristatae 1-19 part, Squama Manis 1-15 part, Semen Vaccariae 1-12 part, Flos Chrysanthemi 1-22 part, Flos Sophorae 1-10 part, Radix Glycyrrhizae Preparata 1-10 part.
3, Chinese medicine composition according to claim 1 and 2, wherein said Flos Semen Lablab Album can substitute with Spica Prunellae;
4, Chinese medicine composition according to claim 1 and 2, wherein said Radix Angelicae Sinensis can substitute with Radix Salviae Miltiorrhizae.
5, Chinese medicine composition according to claim 1 and 2, it is capsule, tablet, pill, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100097592A CN100346802C (en) | 2004-11-08 | 2004-11-08 | Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100097592A CN100346802C (en) | 2004-11-08 | 2004-11-08 | Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1772074A true CN1772074A (en) | 2006-05-17 |
| CN100346802C CN100346802C (en) | 2007-11-07 |
Family
ID=36759325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100097592A Expired - Fee Related CN100346802C (en) | 2004-11-08 | 2004-11-08 | Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100346802C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488763A (en) * | 2011-12-28 | 2012-06-13 | 吕慧侠 | Composition with functions of treating dysmenorrhoea and beautifying |
| CN104491066A (en) * | 2014-12-07 | 2015-04-08 | 苏州普罗达生物科技有限公司 | Flower composition for increasing immunity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060664C (en) * | 1996-07-15 | 2001-01-17 | 鲍树伟 | Chinese drug for curing and preventing mastosis and its preparing method |
| CN1236807C (en) * | 2001-11-05 | 2006-01-18 | 张高军 | Externally applied medicine for treating mastopathy and its prepn |
| CN1240419C (en) * | 2003-11-07 | 2006-02-08 | 徐英 | Mastoplasia treating medicine |
-
2004
- 2004-11-08 CN CNB2004100097592A patent/CN100346802C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488763A (en) * | 2011-12-28 | 2012-06-13 | 吕慧侠 | Composition with functions of treating dysmenorrhoea and beautifying |
| CN102488763B (en) * | 2011-12-28 | 2014-01-08 | 江苏普诺生生物科技有限公司 | A composition with the effect of treating dysmenorrhea and beautifying effect |
| CN104491066A (en) * | 2014-12-07 | 2015-04-08 | 苏州普罗达生物科技有限公司 | Flower composition for increasing immunity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100346802C (en) | 2007-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1061854C (en) | Medicinal preparation for treatment and prevention of gynopathy | |
| CN1857690A (en) | Gynecopathy treating preparation and its preparing process | |
| CN103830577A (en) | Medicine composition for treating liver and gall calculus and kidney stone and application thereof | |
| CN1965990A (en) | Medicament for preventing and treating benign hyperplasia of mammary glands in women and preparation process thereof | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1555816A (en) | Medicne for treating proliferation of mammary gland and its preparing process | |
| CN100446806C (en) | Xinshenghua oral liquid and its preparation method | |
| CN103446500B (en) | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction | |
| CN1289137C (en) | Medicine for treating mammary gland proliferation, its preparation method and application | |
| CN100346802C (en) | Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying | |
| CN103585573B (en) | Oral medicine for treating hysteromyoma | |
| CN1765392A (en) | Chinese compound formulation for nourishing blood, regulating menstruation, stopping bleeding to prevent abortion and preparation method thereof | |
| CN1404867A (en) | Chinese medicine for treating hyperplasia of mammary glands | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN1217680C (en) | Repellent mixture for department of gynecology | |
| CN114288346A (en) | A kind of traditional Chinese medicine composition for treating recurrent miscarriage and application thereof | |
| CN1160089C (en) | Prepn of Xianjia medicine granule for treating hyperprolactin | |
| CN1589894A (en) | Medicinal composition for treating parafunctional metrorrhagia and its preparation method | |
| CN104888153A (en) | Traditional Chinese medicine preparation for treating hepatic hemangioma and preparation method therefor | |
| CN1281262C (en) | Chinese medicine for gynaecological tumor and preparation method | |
| CN110420278A (en) | It is a kind of for treating the pharmaceutical composition of gynecological disease | |
| CN101361955B (en) | Traditional Chinese medicine combination for treating rheumatism | |
| CN103705857B (en) | For preventing the Chinese medicine composition of oral cavity radiomucitis | |
| CN1265810C (en) | A pharmaceutical composition for treating cyclomastopathy, and its preparation method | |
| CN1308031C (en) | Chinese medicine composition for treating biliary tract disease, preparing method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |